US 7479276B1
· Xu et al.
· 2009
[cited by applicant]
US 7780882B2
· Chang et al.
· 2010
[cited by applicant]
US 8617514B2
· Chang et al.
· 2013
[cited by applicant]
US 8859274B2
· Xu et al.
· 2014
[cited by applicant]
US 8865127B2
· Chang et al.
· 2014
[cited by applicant]
US 20050002998A1
· Chang et al.
· 2005
[cited by applicant]
US 20090191261A1
· Xu et al.
· 2009
[cited by applicant]
US 20140356285A1
· Arap et al.
· 2014
[cited by applicant]
US 20190038713A1
· Sobol
· 2019
[cited by examiner]
EP 1811036A2
· 2007
[cited by examiner]
WO 9925320A1
· 1999
[cited by applicant]
WO 2017079746A3
· 2017
[cited by applicant]
Braun et al., “Regulation of Cytotoxic T-cell Responses by p53 in Cancer,” Translational Cancer Research, 5(6): 692-697 (2016).
[cited by applicant]
Buerki et al., “Immunotherapy of Primary Brain Tumors: Facts and Hopes,” Clinical Cancer Research: An Official Journal for the American Association for Cancer Research, 24(21): 5198-5205 (2018).
[cited by applicant]
Camp et al., “Transferrin Receptor Targeting Nanomedicine Delivering Wild-Type p53 Gene Sensitizes Pancreatic Cancer to Gemcitabine Therapy,” Cancer Gene Therapy 20: 222-228 (2013).
[cited by applicant]
Chen et al., “Elements of Cancer Immunity and the Cancer-Immune Set Point,” Nature, 541(7637): 321-330 (2007).
[cited by applicant]
Cui et al., “Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment,” International Journal of Molecular Sciences, 17(11) PMID: 27869779 (2016).
[cited by applicant]
Daud et al., “Programmed Death-ligand 1 Expression and Response to the Anti-programmed Death 1 Antibody Pembrolizumab in Melanoma,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Onco…
[cited by applicant]
Dempke et al., “Programmed Cell Death Ligand-1 (PD-L1) as a Biomarker for Non-Small Cell Lung Cancer (NSCLC) Treatment—Are We Barking up the Wrong Tree?” Translational Lung Cancer Research 7(Suppl 3): S275-S9 (2018).
[cited by applicant]
Descotes et al., “Immunotoxicity of Monoclonal Antibodies,” mAbs, 1(2): 104-111 (2009).
[cited by applicant]
El-Deiry et al., “Insights into Cancer Therapeutic Design Based on p53 and TRIAL Receptor Signaling,” Cell Death and Differentiation, 8(11): 1066-1075 (2001).
[cited by applicant]
El-Deiry et al., “The Role of p53 in Chemosensitivity and Radiosensitivity,” Oncogene, 22(47): 7486-7495 (2003).
[cited by applicant]
Fridman et al., “The Immune Contexture in Human Tumours: Impact on Clinical Outcome,” Nature Reviews Cancer, 12(4): 298-306 (2012).
[cited by applicant]
Gameiro et al., “Radiation-induced Immunogenic Modulation of Tumor Enhances Antigen Processing and Calreticulin Exposure, Resulting in Enhanced T-cell Killing,” Oncotarget 5(2): 403-416 (2014).
[cited by applicant]
Gangadhar et al., “Mitiating the Toxic Effects of Anticancer Immunotherapy,” Nature Reviews Clinical Oncology, 11(2): 91-99 (2014).
[cited by applicant]
Garon et al., “Pembrolizumab for the Treatment of Non-small-cell Lung Cancer,” The New England Journal of Medicine, 372(21): 2018-2028 (2015).
[cited by applicant]
Guo et al., “Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity,” Cancer Research, 77(9): 2292-2305 (2017).
[cited by applicant]
Harter et al., “Distribution and Prognostic Relevance of Tumor-infiltrating Lymphocytes (TILs) and PD-1/PD-L1 Immune Checkpoints in Human Brain Metastases,” Oncotarget, 6(38): 40836-40839 (2015).
[cited by applicant]
Hassel et al., “Combined Immune Checkpoint Blockade (anti-PD-1/anti-CTLA-4): Evaluation and Management of Adverse Drug Reactions,” Cancer Treatment Reviews, 57: 36-49 (2017).
[cited by applicant]
Herbst et al., “Pembrolizumab Versus Docetaxel for Previously Treated, PD-L1-positive, Advanced Non-small-cell Lung Cancer (Keynote-010): A Randomised Controlled Trial,” Lancet, 387(10027): 1540-1550 (2016).
[cited by applicant]
Hirayama et al., “Anti-PD-L1 Treatment Enhances Antitumor Effect of Everolimus in a Mouse Model of Renal Cell Carcinoma,” Cancer Science, 107(12): 1736-1744 (2016).
[cited by applicant]
Holmgaard et al., “Tumor-expressed IDO Recruits and Activates MDSCs in a Treg-dependent Manner,” Cell Reports, 13(2): 412-424 (2015).
[cited by applicant]
Jing et al., “PD-1/PD-L1 Blockades in Non-small-cell Lung Cancer Therapy,” OncoTargets and Therapy, 9: 489-502 (2016).
[cited by applicant]
Kaur et al., “Radiation-induced Effects and the Immune System in Cancer,” Frontiers in Oncology, 2:191 (2012).
[cited by applicant]
Ke et al., “Non-small-cell Lung Cancer-induced Immunosuppression by Increased Human Regulatory T cells via Foxp3 Promoter Demthylation,” Cancer Immunology, Immunotherapy, 65(5): 587-599 (2016).
[cited by applicant]
Kim et al., “Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium,” Journal of Imm. Res., PMID: 26881264 (2016).
[cited by applicant]
Kim et al., “The Clinical Potential of Targeted Nanomedicine: Delivery to Cancer Stem-like Cells,” Molecular Therapy: The Journal of the American Society of Gene Therapy, 22(2): 278-291 (2014).
[cited by applicant]
Kim et al., “A Nanoparticle Carrying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Improves Survival,” ACS Nano., 8(6): 5494-5514 (2014).
[cited by applicant]
Kim et al., “A Tumor-targeting p53 Nanodelivery System Limits Chemoresistance to Temozolomide Prolonging Survival in a Mouse Model of Glioblastoma Multiforme,” Nanomedicine: Nantotechnology, Biology, and Medicine, 11(2)…
[cited by applicant]
Kim et al., “Combination with SGT-53 Overcomes Tumor Resistance to a Checkpoint Inhibitor,” Oncoimmunology, 7(10): e1484982 (2018).
[cited by applicant]
Kudlak et al., “Acute Lung Injury Following the Use of Granulocyte-macrophage Colony-stimulating Factor,” International Journal of Critical Illness and Injury Science, 3(4): 279-281 (2013).
[cited by applicant]
Lechner et al., “Immunogenicity of Murine Solid Tumor Models as a Defining Feature of in vivo Behavior and Response to Immunotherapy,” J. Immunother., 36(9): 477-489 (2013).
[cited by applicant]
Lettau et al., “Insights into the Molecular Regulation of FasL (CD178) Biology,” European Journal of Cell Biology, 90(6-7): 456-466 (2011).
[cited by applicant]
Li et al., “The Role of Adenovirus-mediated Retinoblastoma 94 in the Treatment of Head and Neck Cancer,” Cancer Research 62(16): 4637-4644 (2002).
[cited by applicant]
Mahoney et al., “Combination Cancer Immunotherapy and New Immunomodulatory Targets,” Nature Reviews Drug Discovery, 14(8): 561-584 (2015).
[cited by applicant]
Mall et al., “Repeated PD-1/PD-L1 Monoclonal Antibody Administration Induces Fatal Xenogeneic Hypersensitivity Reactions in a Murine Model of Breast Cancer,” Oncoimmunology, 5(2): e1075114 (2015).
[cited by applicant]
McGuire et al., “Anti-PD-1-induced High-grade Hepatitis Associated with Corticosteroid-resistant T Cells: A Case Report,” Cancer Immunology, Immunotherapy, 67(4): 563-573 (2018).
[cited by applicant]
Mellman et al., “Cancer Immunotherapy Comes of Age,” Nature, 480(7378): 480-489 (2011).
[cited by applicant]
Mello et al., “Deciphering p53 Signaling in Tumor Suppression,” Current Opinion in Cell Biology, 51: 65-72 (2017).
[cited by applicant]
Menendez et al., “Interactions Between the Tumor Suppressor p53 and Immune Responses,” Current Opinion in Oncology, 25(1): 85-92 (2013).
[cited by applicant]
Meslin et al., “Granzyme B-induced Cell Death Involves Induction of p53 Tumor Suppressor Gene and its Activation in Tumor Target Cells,” The Journal of Biological Chemistry, 282(45): 32991-32999 (2007).
[cited by applicant]
Moore et al., “Nanocomplex-based TP53 Gene Therapy Promotes Anti-tumor Immunity Through TP53- and STING-dependent Mechanisms,” Oncoimmunology, 7(7): e1404216 (2018).
[cited by applicant]
Munoz-Fontela et al., “Emerging Roles of p53 and Other Tumour-suppressor Genes in Immune Regulation,” Nature Reviews Immunology, 16(12): 741-750 (2016).
[cited by applicant]
O'Donnell et al., “Acquired Resistance to anti-PD1 Therapy: Checkmate to Checkpoint Blockade?” Genome Medicine, 8(1): 111 (2016).
[cited by applicant]
Ott et al., “Combination Immunotherapy: A Road Map,” Journal for Immunotherapy of Cancer, 5:16 (2017).
[cited by applicant]
Owen-Schaub et al., “Wild-type Human p53 and a Temperature-sensitive Mutant Induce Fas/APO-1 Expression,” Molecular and Cellular Biology, 15(6): 3032-3040 (1995).
[cited by applicant]
Pardoll et al., “The Blockade of Immune Checkpoints in Cancer Immunotherapy,” Nature Reviews Cancer, 12(4): 252-24 (2012).
[cited by applicant]
Pfirschke et al., “Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy,” Immunity, 44(2): 343-354 (2016).
[cited by applicant]
Pirollo et al., “Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene used in Combination with Docetaxel: A Phase 1B Study,” Mol. Ther., 24(9): 1697-1706 (2016).
[cited by applicant]
Prendergast et al., “Discovery of IDO1 Inhibitors: From Bench to Bedside,” Cancer Research, 77(24): 6795-67811 (2017).
[cited by applicant]
Ribas et al., “What Does PD-L1 Positive or Negative Mean?” The Journal of Experimental Medicine, 213(13): 2835-2840 (2016).
[cited by applicant]
Safta et al., “Granzyme B-activated p53 Interacts with Bcl-2 to Promote Cytotoxic Lymphocyte-mediated Apoptosis,” J. Immunol., 194(1): 418-42 (2015).
[cited by applicant]
Senzer et al., “Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors,” Molecular Therapy: The Journal of the American Society of Gene Therapy, 21(5): 1096-1103 (2013).
[cited by applicant]
Sica et al., “Macrophage Polarization in Tumour Progression,” Seminars in Cancer Biology, 18(5): 349-355 (2008).
[cited by applicant]
Siefker-Radke et al., “A Phase | Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancer,” Mol. Ther., 24(8): 1484-1491 (2016).
[cited by applicant]
Soussi et al., “Shaping Genetic Alterations in Human Cancer: the p53 Mutation Paradigm,” Cancer Cell, 12(4): 303-312 (2007).
[cited by applicant]
Syn et al., “De-novo and Acquired Resistance to Immune Checkpoint Targeting,” The Lancet Oncology, 18(12): e731-e741 (2017).
[cited by applicant]
Taube et al., “Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to anti-PD-1 Therapy,” Clinical Cancer Research: An Official Journal of the American Association fo…
[cited by applicant]
Thiery et al., “p53 Potentiation of Tumor Cell Susceptibility to CTL Involves Fas and Mitochondrial Pathways,” J. Immunol., 174(2): 871-878 (2005).
[cited by applicant]
Valente et al., “p53 as the Focus of Gene Therapy: Past, Present and Future,” Current Drug Targets, PMID: 29336259 (2018).
[cited by applicant]
Wang et al., “p53 Increases MHC Class | Expression by Upregulating the Endoplasmic Reticulum Aminopeptidase ERAP1,” Nature Communications, 4: 2359 (2013).
[cited by applicant]
Wang et al., “Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-pD-1 Treatment That Can be Overcome by Radiotherapy,” Cancer Research, 77(4): 839-850 (2017).
[cited by applicant]
Willingham et al., “The CD47-signal Regulatory Protein Alpha (SIRPa) Interaction is a Therapeutic Target for Human Solid Tumors,” PNAS, 109(17): 6662-6667 (2012).
[cited by applicant]
Xu et al., “Transferrin-liposome-mediated Systemic p53 Gene Therapy in Combination with Radiation Results in Regression of Human Head and Neck Cancer Xenografts,” Human Gene Therapy, 10(18): 2941-2952 (1999).
[cited by applicant]
Yu et al., “Allele-specific 53 Mutant Reactivation,” Cancer Cell 21(5): 614-625 (2012).
[cited by applicant]
Zaretsky et al., “Mutations Associated with Acquired Resistance to PD-1 Blockade | Melanoma,” The New England Journal of Medicine, 375(9): 819-829 (2016).
[cited by applicant]
Zeng et al., “Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice with Intracranial Gliomas,” International Journal of Radiation Oncology, Biology, Physics, 86(2): 343-349 (2013).
[cited by applicant]
Zhang et al., “Adenoviral-mediated Retinoblastoma 94 Produces Rapid Telomere Erosion, Chromosomal Crisis, and Caspase-dependent Apoptosis in Bladder Cancer and Immortalized Human Urothelial Cells but not in Normal Uroth…
[cited by applicant]
Zhou et al., “The Oncolytic Peptide LTX-315 Triggers Immunogenic Cell Death,” Cell Death & Disease, 7: e2134 (2016).
[cited by applicant]
Zhu et al., “p53 Induces TAP1 and Enhances the Transport of MHC Class | Peptides,” Oncogene, 18(54): 7740-7747 (1999).
[cited by applicant]
Zou et al., “PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers, and Combinations,” Science Translational Medicine, 8(328): 328r4 (2016).
[cited by applicant]